Roth Capital Reiterates Buy On Celldex Following Initiation Of Phase Ib Combination Study
Roth Capital analyst Joseph Pantginis reiterated Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $40 price target, as Celldex and Oncothyreon (NASDAQ:ONTY) have initiated a Phase Ib combination study of varlimumab and ONT-10 in advanced breast and ovarian cancer patients.
Pantginis noted, “As we move into 2015, we expect the initiation of multiple combination studies with varli based on its robust immune stimulatory properties. These include ONT-10, Opdivo (nivolumab), Yervoy (ipilimumab) and other planned combos. We are enthusiastic for the potential of varli to potentiate the ONT-10 vaccine approach.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -4.9% and a 45.6% success rate. Pantginis has a -2.1% average return when recommending CLDX, and is ranked #3285 out of 3367 analysts.